2,5-Dioxopyrrolidin-1-yl 3',6'-bis(dimethylamino)-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-5-carboxylate

Catalog No. :
ACYHZI246
CAS No. :
321862-17-3
Molecular Formula :
C29H25N3O7
Molecular Weight :
527.53

IUPAC Name:2,5-dioxopyrrolidin-1-yl 3',6'-bis(dimethylamino)-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-5-carboxylate

2,5-Dioxopyrrolidin-1-yl 3',6'-bis(dimethylamino)-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-5-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2,5-Dioxopyrrolidin-1-yl 3',6'-bis(dimethylamino)-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-5-carboxylate
IUPAC Name2,5-dioxopyrrolidin-1-yl 3',6'-bis(dimethylamino)-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-5-carboxylate
Molecular FormulaC29H25N3O7
Molecular Weight527.53
SMILESCN(C)C1=CC2=C(C=C1)C1(OC(=O)C3=CC(C(=O)ON4C(=O)CCC4=O)=CC=C31)C1=C(C=C(N(C)C)C=C1)O2
InChI KeyCXYYHBMOVJJZTD-UHFFFAOYSA-N
Synonym5-TAMRA NHS ester;TAMRA NHS ester, 5-isomer;5-TAMRA-OSu;5/6-TAMRA-OSu;Spiro[isobenzofuran-1(3H),9'-[9H]xanthene]-5-carboxylic acid, 3',6'-bis(dimethylamino)-3-oxo-, 2,5-dioxo-1-pyrrolidinyl ester
CAS No.321862-17-3

Synthetic Route by SureRoute

1. ACYHZI246 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACMYHT018 route compound structure diagram
    ACMYHT018150322-05-7 In Stock
  2. Plus
  3. ACPOQL635 route compound structure diagram
    ACPOQL6356066-82-6 In Stock
  4. Then
  5. ACYHZI246 route product structure diagram
    ACYHZI246321862-17-3
Inquiry

2. ACYHZI246 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACYHZI246 route product structure diagram
    ACYHZI246321862-17-3
Inquiry

Comments (0)